Literature DB >> 16450341

Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability.

D Guenot1, E Guérin, S Aguillon-Romain, E Pencreach, A Schneider, A Neuville, M-P Chenard, I Duluc, S Du Manoir, C Brigand, P Oudet, M Kedinger, M-P Gaub.   

Abstract

Evaluation of the role of clonal heterogeneity in colon tumour sensitivity/resistance to drugs and/or in conferring metastatic potential requires an adequate experimental model in which the tumour cells maintain the initial genetic alterations and intra-tumoral heterogeneity through maintenance of the genetic clones present in the initial tumour. Therefore, we xenografted subcutaneously into nude mice seven human colonic tumours (from stages B1 to D) that showed chromosome instability and transplanted them sequentially for up to 14 passages. Maintenance after xenografting of the genetic alterations present in the initial tumours was scored by allelotype studies targeting 45 loci localized on 18 chromosomes. We show that xenografting does not alter the genetic or the histological profiles of the tumours even after 14 passages. Screening of the entire genome of one tumour by comparative genome hybridization also showed overall stability of the alterations between the initial and the xenografted tumour. In addition, intra-tumoral heterogeneity was maintained over time, suggesting that no clonal selection occurred in the nude mice. The observation that some loci showed partial allelic imbalance in the initial tumour but loss of heterozygosity after the first passage in nude mice when all the normal cells were lost may allow identification of interesting genetic defects that could be involved in tumour expansion. Thus, sequential xenografts of colon tumours will provide a powerful model for further study of tumour clonality and for the identification of genetic profiles responsible for differential resistance to therapeutic treatments. Our data also suggest that tumour expansion can result from alterations in several distinct genetic pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16450341     DOI: 10.1002/path.1936

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  30 in total

Review 1.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

2.  The microenvironment controls CDX2 homeobox gene expression in colorectal cancer cells.

Authors:  Fairouz Benahmed; Isabelle Gross; Dominique Guenot; Frédéric Jehan; Elisabeth Martin; Claire Domon-Dell; Thomas Brabletz; Michèle Kedinger; Jean-Noël Freund; Isabelle Duluc
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Patient-derived xenograft models in gynecologic malignancies.

Authors:  Clare L Scott; Helen J Mackay; Paul Haluska
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

4.  Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement.

Authors:  Celia Chao; Steve G Widen; Thomas G Wood; John R Zatarain; Paul Johnson; Aakash Gajjar; Guillermo Gomez; Suimin Qiu; Jill Thompson; Heidi Spratt; Mark R Hellmich
Journal:  Anticancer Res       Date:  2017-07       Impact factor: 2.480

5.  In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.

Authors:  Eric Guérin; Wolfgang Raffelsberger; Erwan Pencreach; Armin Maier; Agnès Neuville; Anne Schneider; Philippe Bachellier; Serge Rohr; Amélie Petitprez; Olivier Poch; Dino Moras; Pierre Oudet; Annette K Larsen; Marie-Pierre Gaub; Dominique Guenot
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 6.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

7.  Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs.

Authors:  Guangzhong Xu; Kai Li; Nengwei Zhang; Bin Zhu; Guosheng Feng; Qing Fan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

8.  Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment.

Authors:  Benoît Romain; Agnès Neuville; Nicolas Meyer; Cécile Brigand; Serge Rohr; Anne Schneider; Marie-Pierre Gaub; Dominique Guenot
Journal:  BMC Cancer       Date:  2010-10-18       Impact factor: 4.430

9.  Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  David Roife; Bingbing Dai; Ya'an Kang; Mayrim V Rios Perez; Michael Pratt; Xinqun Li; Jason B Fleming
Journal:  Clin Cancer Res       Date:  2016-06-03       Impact factor: 12.531

10.  Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation.

Authors:  José Miguel Pardo-Sánchez; Nuria Mancheño; José Cerón; Carlos Jordá; Emilio Ansotegui; Óscar Juan; Sarai Palanca; Antonio Cremades; Carolina Gandía; Rosa Farràs
Journal:  Cancers (Basel)       Date:  2021-06-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.